Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc.（RCKT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · RCKT · 截至 2026年6月9日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
32
近12个月
买卖比
0.06
Buy/Sell (by trades)
整体情绪
Rocket Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
RCKT 季度内部人买卖趋势
RCKT 内幕交易卖出 · RCKT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · RCKT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
RCKT 高管卖出股份 · RCKT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 21, 2026 | Shah Gaurav CEO | Option | 76,490 | $129K | Form 4 |
| May 21, 2026 | Shah Gaurav CEO | Sale | 55,684 | $172K | Form 4 |
| May 19, 2026 | Shah Gaurav CEO | Sale | 2,409 | $7K | Form 4 |
| May 19, 2026 | Wilson Martin General Counsel | Sale | 662 | $2K | Form 4 |
| May 19, 2026 | Militello John See Remarks | Sale | 384 | $1K | Form 4 |
| May 13, 2026 | Wilson Martin General Counsel | Sale | 3,361 | $12K | Form 4 |
| May 13, 2026 | Shah Gaurav CEO | Sale | 2,728 | $10K | Form 4 |
| May 13, 2026 | Militello John See Remarks | Sale | 855 | $3K | Form 4 |
| May 7, 2026 | Chaudhuri Sarbani See Remarks | Sale | 17,650 | $68K | Form 4 |
| Feb 18, 2026 | Militello John See Remarks | Sale | 1,157 | $4K | Form 4 |
| Feb 18, 2026 | Shah Gaurav CEO | Sale | 5,990 | $20K | Form 4 |
| Feb 18, 2026 | Wilson Martin General Counsel | Sale | 1,376 | $5K | Form 4 |
| Feb 13, 2026 | Wilson Martin General Counsel | Sale | 12,253 | $41K | Form 4 |
| Feb 13, 2026 | Militello John See Remarks | Sale | 3,726 | $12K | Form 4 |
| Feb 13, 2026 | Shah Gaurav CEO | Sale | 12,279 | $41K | Form 4 |
| Feb 11, 2026 | Shah Gaurav CEO | Award | 286,028 | — | Form 4 |
| Feb 11, 2026 | Militello John See Remarks | Award | 29,982 | — | Form 4 |
| Feb 11, 2026 | Wilson Martin General Counsel | Award | 311,813 | — | Form 4 |
| Feb 11, 2026 | Rizvi Syed Ali-aamir Chief Medical Officer | Award | 61,963 | — | Form 4 |
| Feb 11, 2026 | Stevens Christopher James COO | Award | 61,963 | — | Form 4 |
| Feb 11, 2026 | Chaudhuri Sarbani See Remarks | Award | 125,924 | — | Form 4 |
| Jan 2, 2026 | Bjork Elisabeth Director | Purchase | 10,000 | $34K | Form 4 |
| Nov 18, 2025 | Schwartz Jonathan David See Remarks | Sale | 2,545 | $8K | Form 4 |
| Nov 18, 2025 | Shah Gaurav CEO · Director | Sale | 6,276 | $19K | Form 4 |
| Nov 18, 2025 | Militello John See Remarks | Sale | 1,086 | $3K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 RCKT 内幕交易
RCKT 内幕交易
Rocket Pharmaceuticals, Inc.（RCKT）内幕交易数据来源于公司内部人（包括Militello John (See Remarks), Wilson Martin (General Counsel), Shah Gaurav (CEO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。RCKT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Rocket Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
RCKT 内幕交易 · 5个问题Rocket Pharmaceuticals, Inc.（RCKT）的内部人包括高管和董事，如Militello John (See Remarks), Wilson Martin (General Counsel), Shah Gaurav (CEO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026